Verici Dx plc (LON:VRCI – Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as GBX 4 ($0.05) and last traded at GBX 4 ($0.05), with a volume of 210052 shares. The stock had previously closed at GBX 4.25 ($0.06).
Verici Dx Trading Down 3.4 %
The business’s 50-day moving average is GBX 6.31 and its two-hundred day moving average is GBX 6.98. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.54 and a quick ratio of 8.49. The firm has a market cap of £8.49 million, a P/E ratio of -162.50 and a beta of 1.59.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Read More
- Five stocks we like better than Verici Dx
- Stock Sentiment Analysis: How it Works
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
